Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evidence for linkage of migraine in Rolandic epilepsy to known 1q23 FHM2 and novel 17q22 genetic loci.

Genes, brain, and behavior·2013

Same author

Research challenges in central nervous system manifestations of inborn errors of metabolism.

Molecular genetics and metabolism·2010

Same author

Ischemic stroke and rhabdomyolysis in a 15-year-old girl with paraganglioma due to an SDHB exon 6 (Q214X) mutation.

Journal of pediatric endocrinology & metabolism : JPEM·2009

Same author

Treatment strategies for medulloblastoma and primitive neuroectodermal tumors.

Neurosurgical focus·2006

Same author

Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.

Neurology·2003

Same author

Clinical, genetic and histopathologic findings in two siblings with muscle-eye-brain disease.

European journal of ophthalmology·2002

Search research articles

Related Experiment Video

Updated: Jul 28, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7,200 cGy.

R J Packer¹, J C Allen, J L Goldwein

¹Children's Hospital of Philadelphia, Division of Neurology, PA 19104.

Annals of Neurology

|February 1, 1990

Summary

High-risk childhood brainstem gliomas show improved outcomes with hyperfractionated radiotherapy. A trial using 7,200 cGy demonstrated a statistically significant increase in progression-free survival compared to lower doses.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jul 28, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

Area of Science:

Pediatric Oncology
Radiation Oncology
Neuro-Oncology

Background:

Brainstem gliomas are aggressive childhood central nervous system tumors, notoriously resistant to therapy.
High-risk cases, with diffuse involvement or anaplasia, have a poor prognosis despite conventional radiotherapy.
Hyperfractionated radiotherapy offers a potential strategy to enhance tumor control without increasing toxicity.

Purpose of the Study:

To evaluate the efficacy and safety of a higher dose of hyperfractionated radiotherapy in high-risk pediatric brainstem gliomas.
To compare outcomes with historical controls and previous lower-dose hyperfractionation regimens.

Main Methods:

A multiinstitutional phase I/II trial was conducted for high-risk brainstem glioma patients.
Treatment involved hyperfractionated radiotherapy at 100 cGy twice daily to a total dose of 7,200 cGy.
Patient responses, progression-free survival, and toxicity were assessed.

Main Results:

A 30% actuarial progression-free survival at 20 months was observed.
Twenty-three of 31 evaluable patients showed an objective radiographic response.
Statistically significant improvement in progression-free survival was noted compared to historical controls and a 6,480 cGy regimen (p < 0.01).

Conclusions:

Higher-dose hyperfractionated radiotherapy (7,200 cGy) significantly improves progression-free survival in high-risk pediatric brainstem gliomas.
The treatment was well-tolerated, with transient side effects and no treatment-related deaths.
This regimen represents a promising advancement for managing these challenging tumors.